[procaare] Bacteria May Show Promise in AIDS Fight

[ProCAARE <procaare@healthnet.org>]

Bacteria May Show Promise in AIDS Fight
Associated Press - Tuesday, September 9, 2003
Randolph E. Schmid
***********************

WASHINGTON - A modified form of bacteria normally present in the vagina may one day be
used to protect women from AIDS, according to new research.

The engineered bacteria showed promise in laboratory testing, and researchers now plan to
try them out in animals, said John A. Lewicki of Osel Inc., in Santa Clara, Calif.

The most common way AIDS is transmitted is through heterosexual intercourse, with women
particularly vulnerable in countries where condoms and other protective measures are less
available.

Researchers used a strain of Lactobacillus jensenii, generally abundant in mucus secreted
by the mucous membrane lining a healthy vagina. The bacteria were modified to produce a
protein called CD4, which binds to the HIV virus that causes AIDS.

In laboratory tests, the enhanced bacteria reduced the rate of HIV infection in
susceptible cells by at least half, the researchers said. Their findings are reported in
this week's online issue of Proceedings of the National Academy of Science.

"The paper presents our first prototype for a product that will come to use," Lewicki said
in a telephone interview. His company develops therapeutic products from common bacteria.

"This is something we believe is moving toward a clinical reality," he said. But, he said,
animal testing is needed and the developers will work closely with the Food and Drug
Administration before human testing can be done.

Roberta Black, the topical microbicide team leader at the National Institute of Allergy
and Infectious Disease, said the researchers "have shown proof of concept in the
laboratory, and that's certainly where everything starts, ... but it's a big jump to
people."

Nonetheless, she said, this is a "highly innovative approach that exploits a naturally
occurring defense mechanism."

The researchers need to avoid problems like that with nonoxynol-9, a microbicide that was
promoted for similar use, but it irritated vaginal tissue and increased the chance of HIV
infection.

Lactobacillus works differently from nonoxynol-9, Lewicki stressed, by enhancing the
protective bacteria rather than damaging them.

The research was led by Peter P. Lee of Stanford University, who said in a statement that
he envisions the research eventually leading to creation of a small vaginal suppository
that a woman could use on a regular basis.

"It would be as discreet as can be," said Lee, adding that each dose could last a week or
longer and could be inserted at any time. He said he hopes to translate the technology to
other viruses, such as the human papilloma virus, the herpes virus, even the common cold
or flu.

Copyright (c) 2003 - Associated Press.

Source: AEGIS - Sept 10 2003
http://www.aegis.org/news/ap/2003/AP030907.html

--
ProCAARE is currently supporting the 6th Home and Community Care
Conference in Dakar, Senegal (December 8 - 12, 2003).
For more information: http://www.dakarvih2003.sn/

To send a message to ProCAARE, write to: procaare@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe procaare OR unsubscribe procaare
To contact a person, send a message to: procaare-help@healthnet.org
Information and archives: http://www.procaare.org

The views presented in ProCAARE do not necessarily reflect the opinions of
SATELLIFE  (http://www.healthnet.org), the Harvard AIDS Institute
(http://aids.harvard.edu), or Health & Development Networks
(http://www.hdnet.org), unless otherwise stated. The reader assumes all
responsibilities in using information posted or archived by ProCAARE.
Reproduction is welcomed, provided ProCAARE and procaare@healthnet.org
are quoted, and SATELLIFE is informed of usage.